EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Evommune, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$5.27+0.10 (+1.93%)

Close on Oct 19, 2026

Market cap: $190.43M
P/E (TTM): –
Dividend yield: –

Evommune, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Cash & Equivalents	44	16	29
Short-Term Investments	105	56	–
Cash & Short-Term Investments	149	72	29
Prepaid Expenses & Other	4.28	1.95	–
Total Current Assets	153	74	–
Property, Plant & Equipment	0.99	1.33	–
Gross Property, Plant & Equipment	2.55	2.27	–
Accumulated Depreciation	-1.56	-0.95	–
Long-Term Investments	67	–	–
Operating Lease Right-of-Use Assets	1.47	0.47	–
Other Long-Term Assets	0.10	0.06	–
Total Assets	225	76	–
Accounts Payable	7.76	8.26	–
Accrued Expenses	9.55	6.73	–
Current Portion of Leases	0.24	0.49	–
Deferred Revenue (Current)	–	3.00	–
Other Current Liabilities	0.36	0.57	–
Total Current Liabilities	18	28	–
Long-Term Leases	1.29	–	–
Operating Lease Liabilities	1.53	0.49	–
Other Long-Term Liabilities	–	0.54	–
Total Liabilities	19	29	–
Common Stock	0.00	0	–
Additional Paid-In Capital	427	7.98	–
Retained Earnings	-221	-152	–
Shareholders' Equity	206	-144	-78
Total Equity	206	-144	-78
Total Liabilities & Equity	225	76	–
Shares Outstanding(shares)	32	1.55	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1018.9%
Net margin: -946.7%
Return on equity, FY2025: -224.6%

Financial strength

Current ratio: 11.68
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 343.3%

Valuation

P/E ratio: –
Price to sales: 19.04
Price to book: 0.69
Dividend yield: –